Shinjuku NS Building

Trailstone Welcomes Energy Industry Veterans to Lead Japanese Operations

Retrieved on: 
Wednesday, May 24, 2023
Software, Utilities, Data Analytics, Alternative Energy, Energy, Artificial Intelligence, Professional Services, Technology, EEX, European Energy Exchange, Japan Electric Power Exchange, Risk management, M&A, Nishi-Shinjuku, JEPX, Professional, Growth, Commercial, Shinjuku NS Building, METI, PPA, Sumitomo Group, Environment, Renewable energy, Cryptocurrency, Itochu

Kamisago brings over 25 years of experience in international business development with Sumitomo and Itochu, two of the largest Japanese trading and investment firms.

Key Points: 
  • Kamisago brings over 25 years of experience in international business development with Sumitomo and Itochu, two of the largest Japanese trading and investment firms.
  • He is an expert in M&A, new investment, infrastructure project management and new business incubation in the global energy industry.
  • Most recently, Kamisago led Sumitomo’s energy, environment and green hydrogen businesses as a general manager, gaining experience in both domestic and international business settings.
  • “Japanese power markets and renewable energy generators can benefit greatly from Trailstone’s extensive experience in Europe and the United States,” said Kamisago.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
Wednesday, May 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.